MedPath

EURO-STIM Registry

Not yet recruiting
Conditions
Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Registration Number
NCT06971796
Lead Sponsor
Inspire Medical Systems, Inc.
Brief Summary

The registry is to measure longitudinal outcomes and adherence of the Inspire System. The goal of the registry is to capture the life cycle of the patient's use of the Inspire System through routine clinical care visits. There are no required interventions or testing.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria

Any patient implanted with or receiving an Inspire implant, who meets the following criteria, is eligible to participate in the registry:

  1. Capable of giving informed consent, as required per institution
  2. Willing to return for routine clinic visits as required for Inspire therapy management
Exclusion Criteria

Any patient who meets any of the following criteria will not be eligible to participate in the registry:

  1. Has a life expectancy of less than one year
  2. Any reason the clinician deems patient is unfit for participation in the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Apnea Hypopnea Index (AHI)Total AHI, supine and non-supine AHI, documented as events/hour of sleep will be collected at baseline, prior to implant, and at follow-up visits, if available, as determined by clinical standard of care.

The AHI, or number of apnea and hypopnea events per hour, is a measure of OSA severity.

Epworth Sleepiness Scale (ESS)ESS will be collected at baseline and follow-up visits, if available, as determined by clinical standard of care.

The ESS is a validated, self-report instrument that rates a subject's tendency to fall asleep in eight common daily situations13. The ESS has been validated primarily in OSA.

Secondary Outcome Measures
NameTimeMethod
Therapy UseTherapy use will be collected at follow-up visits after device activation, if available.

Therapy use, reported as hours of use per week, is recorded during follow-up visits and will be collected from the Inspire physician programmer.

Adverse EventsThe number of events (as well as the % of subjects in which the event occurred) will be reported at implant and at follow-up timepoints.

Both serious and non-serious procedure-related and device/therapy related adverse events will be collected and reported.

DISE VOTE ClassificationDISE VOTE Score will be collected, if available, at baseline.

A Drug-Induced Sleep Endoscopy (DISE) is a diagnostic, standard of care procedure performed as part of the evaluation for airway surgeries (including implant of the Inspire System). The DISE is utilized to visualize the patient's airway obstruction.

Functional Outcomes of Sleep Questionnaire (FOSQ-30)FOSQ-30 will be collected at baseline and follow-up visits, if available and only if already collected as part of routine clinical care.

The FOSQ-30 is a validated, quality of life measurement that assesses the effect of a subject's daytime sleepiness on activities of ordinary living. It is commonly used in the clinical evaluation and management of OSA.

Patient Experience with Therapy (PET)PET will be collected at follow-up visits after device activation, if available.

The PET is a survey designed to collect information about patient's experience with the Inspire therapy.

Maintenance of Wakefulness Test (MWT)Sleep latency is recorded in minutes and may be collected from a maintenance of wakefulness test performed at baseline and follow-up visits after device activation, if available.

The maintenance of wakefulness test is used to measure a person's ability to stay awake during a defined period of time.

© Copyright 2025. All Rights Reserved by MedPath